Thiogenesis Therapeutics, Corp. (TSXV: TTI)
Health Care · Biotechnology · CA
CA$0.50
-5.66% today · -26.5% 1Y
Thiogenesis Therapeutics, Corp. (TSXV: TTI) operates in the Biotechnology industry within the Health Care sector. The company is valued at $24.74M.
Over the last twelve months the share price has lost 26.5%, trading between 0.44 and 0.81.
Tweenvest scores Thiogenesis Therapeutics, Corp. across four factors: quality 35/100, value 22/100. Its strongest factor is quality.
TTI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $24.74M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.12
- Dividend yield
- —
- Beta (5Y)
- 0.61
- 52-week high
- CA$0.81
- 52-week low
- CA$0.44
- Avg volume (3M)
- —
- Shares outstanding
- 69.98M
- Employees
- —
- Next earnings
- —
About Thiogenesis Therapeutics, Corp.
Thiogenesis Therapeutics Corp. engages in the development of novel drug formulations that act as precursors for rare diseases. The company was founded on May 3, 2018 and is headquartered in Toronto, Canada.
- ISIN
- CA88410L1022
- Listed since
- Apr 13, 2022
- Exchange
- TSX Venture Exchange
- Currency
- CAD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Kainos Medicine, Inc.KOSDAQ: A284620 | $25.58M | ₩— | — |
| D. Western Therapeutics Institute, Inc.TSE: 4576 | $25.15M | ¥69.00 | -1.43% |
| Immutep LimitedASX: IMM | $24.85M | AU$0.02 | +4.35% |
| Genvor IncorporatedOTCPK: GNVR | $24.85M | $0.68 | -24.17% |
| Seres Therapeutics, Inc.NasdaqGS: MCRB | $24.71M | $2.46 | -9.23% |
| Lukas Biomedical Inc.TPEX: 6814 | $24.52M | NT$19.00 | +2.70% |
| Original BioMedicals Co., Ltd.TPEX: 6483 | $24.50M | NT$11.90 | +3.93% |
| Ribomic Inc.TSE: 4591 | $24.36M | ¥68.00 | -4.23% |
Figures last refreshed Oct 18, 2026.